Back to search results

Adaptive Radiation Planning for Lung Cancer

This study is looking at a new way to plan radiation treatment for people with stage II-IV non-small cell lung cancer. When you get radiation, your tumor might shrink, which means healthy tissue could be exposed to radiation. This study uses "adaptive radiation planning," which means your treatment plan is adjusted over time to make sure the radiation targets only the tumor. The goal is to see if this method can reduce side effects like lung inflammation (pneumonitis) that can happen with radiation and immunotherapy. To join, you need to have locally advanced or metastatic non-small cell lung cancer that will be treated with chemoradiation, possibly with immunotherapy. The study aims to see if this adaptive planning reduces pneumonitis rates within 6 months after treatment.

Study design
This is an interventional study with a planned enrollment of 34 participants. It is designed to evaluate whether adaptive radiation planning reduces cardiopulmonary toxicity.
What's involved
You would undergo CT scans for planning, then receive standard chemoradiation. Additional CT scans would be done on days 15 and 29 of treatment. The total treatment period is about 40 days.
Compensation
Not stated in the trial record.
Follow-up
After treatment, you would have follow-up visits at 3-12 weeks, and then every 6 months for about 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04751747

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
Rutgers, The State University of New Jersey
~34 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Computed TomographyContrast Agent

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine if adaptive radiation therapy reduces radiation induced pneumonitis rates
Measured over At 6 months post chemoradiation

Conditions

Locally Advanced Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

2 sites across 1 states
New Jersey2

Study leadership

  • Salma K Jabbour, MD · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
Histologically or cytological evidence of locally advanced, biopsy-proven, stage II (inoperable), III-or oligometastatic stage IV NSCLC planned to be treated with chemoradiation with concurrent or adjuvant immunotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ and marrow laboratory values for radiation therapy deemed by appropriate the investigator obtained within 14 days prior to registration for protocol therapy
Women of childbearing potential (WOCBP) must obtain a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) at day -30 to day 0
Women of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of contraception during the time of the study period
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year

Exclusion

History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the site investigator
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
Active central nervous system (CNS) metastases (if symptomatic or without prior brain imaging, subjects must undergo a head computed tomography \[CT\] scan or brain magnetic resonance imaging \[MRI\] within 28 days prior to registration for protocol therapy to exclude brain metastases)
Treatment with any investigational agent within 28 days prior to registration for protocol therapy
Prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer other than standard concurrent chemoradiation or up to 2 cycles of consolidation therapy
Active second cancers
History of psychiatric illness or social situations that would limit compliance with study requirements

What this trial measures

  • Determine if adaptive radiation therapy reduces radiation induced pneumonitis ratesAt 6 months post chemoradiation

    Will be analyzed using a one-sided z-test to determine if reduction in radiation doses to organs at risk compared will result in a lower rate of pneumonitis compared to historical controls.